 PSEN1 mutation carrier status was associated with mean diffusivity (MD) change.
Introduction
Alzheimer's disease (AD) is the most common neurodegenerative disease in the world. So far, the molecular, genetic and biochemical properties of the disease remain unclear and remain to be studied [1] . In a family with dominant familial AD (FAD), approximately half of siblings are mutation carriers (MC), and AD usually occurs at an earlier age. Three mutations have been found: presenilin 1 (PSEN1), presenilin 2 (PSEN2) and amyloid precursor protein (APP) [2] [3] [4] . Pathological features of FAD include A C C E P T E D M A N U S C R I P T neurofibrillary tangles (NFT), amyloid plaques (APs), neuronal loss, and brain atrophy, similar to sporadic AD [5] . AD is characterized by intracellular neurofibrillary tangles and amyloid plaques.
Pathologically, cumulative accumulation of NFT and AP in brain tissue ultimately leads to neuronal death and gray matter (GM) atrophy [6, 7] , all of which can be measured by imaging techniques such as magnetic resonance imaging (MRI).
The degeneration of AD mainly affects gray matter (GM), and the evidence also indicates that early white matter (WM) also has defects [8] . In AD disease, WM abnormalities have been reported using diffusion tensor imaging (DTI) [9] . Both autopsy studies [10, 11] and magnetic resonance imaging (MRI) studies [12] [13] [14] have showed evidence of defects of white matter (WM) defects in AD.
In addition, there is a significant correlation between disease severity and WM indicators [15, 16] , which provides evidence that white matter measurements can be used as markers of AD disease progression. MRI techniques, such as diffusion tensor imaging (DTI), can study the direction and integrity of WM bundles by measuring the diffusion of water molecules in nerves and axons [17] . The mean diffusivity (MD) and fractional anisotropy (FA) are the two most common measurement methods in DTI. MD provides a marker of isotropic diffusion of water molecules and FA measure the anisotropic water diffusion. Ringman et al found that FA decreased in the fornix of pre-MCs and early symptomatic MCs . [18] . Recently, Ryan et al found that patients with symptomatic MC had significantly increased MD and decreased FA compared with healthy controls [19] . In addition, biochemical abnormalities in the cerebrospinal fluid (CSF) [20] [21] [22] and fibrillar amyloidosis, using positron emission tomography imaging of brain amyloid [23] , have also been reported in symptomatic MCs.
Overall, higher MD and lower FA values were detected in DTI studies in the AD and MCI groups compared to controls. Despite this, there is a large amount of heterogeneity in different brain regions and different studies. Although there are some DTI descriptive studies on AD and MCI [24] [25] [26] .
However, to date, no studies have been conducted to quantitatively assess the relationship between PSEN1 genotype and white matter integrity and metabolic changes. Therefore, our goal is to provide a meta-analysis and systematic review to assess the relationship between PSEN1 mutations and white matter abnormalities and metabolic changes. Here, related neuroimaging markers mainly include MD values; Aβ deposition and glucose metabolism.
Methods

Search strategy and selection criteria
The literature published from January 1, 1997 to May 1, 2018 was systematically screened in PubMed, MEDLINE, and EMBASE. Use the following terms in the title, abstract or descriptor according to the preferred report item of the Systematic Review and Meta-analysis (PRISMA) guide: PSEN1, presenlin1, MRI, DTI, PET, glucose metabolism, PiB, amyloid, Alzheimer disease, AD. We limit our search to human research. The detailed Boolean operators as follows("PSEN1" OR "presenilin 1") AND ("Magnetic Resonance Imaging " OR "MRI ") AND ("Positron emission tomography " OR "PET ") AND ("glucose metabolism " OR "PiB-PET" OR "Pittsburgh compound B-PET") AND ("Alzheimer disease " OR "AD").
Our included study tested the association of PSEN1 with at least one neuroimaging marker of white matter changes and cortical metabolism. The following are the criteria included: (1) original research; (2) 
Data extraction and quality assessment
The following data were independently extracted by two authors: sample size, study population, mean age, DTI characteristics and sequences, PET characteristics and related technical details. To measure the association between PSEN1 and MRI markers, we recorded the mean, SD or SE for the continuous MD value. To measure the association between PSEN1 genotype and PET markers, the mean and SD on 
Statistical analyses
Meta-analysis was performed when at least three studies were available for the same outcome. Here, PSEN1+ was defined as a homozygous wild type genotype, and PSEN1-means heterozygous dominant mutation. To compare the association between different genotypes (PSEN1+ Vs. PSEN1-) and MD values. We summarized the MD values changes of each groups separately. For MD value change, Pib-PET and FDG-PET calculation, meta-analysis of all statistics was performed using standard mean difference (SMD) methodology in Stata 12.0 software (Stata Corp, College Station, TX, USA). A random-effects model was used if the heterogeneity between studies was statistically significant and a fixed-effects meta-analysis was used in the absence of heterogeneity. Overall, heterogeneity was assessed using the Cochran Q (p value >0.10 on the Q test, which reflects a lack of heterogeneity among studies) and I 2 (considerable heterogeneity: values of more than 50%) [27, 28] . The 95% CI was used to gauge the precision of the summary estimates.
Results
The initial literature searches identified 163 potentially relevant articles, of which 123 met the inclusion criteria. By screening the full text, 96 articles were excluded because of different reasons ( Figure 1 ). Figure. 1 showed the flow chart of the identification and attrition of studies, and Tables 1 and 2 show the key details of the studies included in the meta-analysis.
Finally, 11 studies that were published between 2008 and 2018 met the selection criteria, including access to information on the association between PSEN1 and the three neuroimaging biomarkers. A total of 317 PSEN1+ subjects and 260 PSEN1-subjects were included. No outliers were found by the sensitivity analysis in this study. There was statistically significant change in the pooled SMD for MD change (SMD was between 1.04 and 3.53) or for the amyloid PET analysis (SMD was between 0.25 and 7.08) and no significant change for FDG-PET analysis (SMD was between -3.17 to 0.12).
PSEN1+ and DTI marker of AD (white matter MD value)
Description of studies Seven studies investigated the association between PSEN1+ and MD value change. Three studies could
not be used for analysis [29] [30] [31] . Hence, a total of four studies which met criteria were included into our meta-analysis [32] [33] [34] [35] , totally including 210 PSEN1+ carriers and 150 PSEN1-carriers. Of the included studies, all reported the MD value was significantly increased in PSEN1 mutation subjects than in PSEN1+ subjects. The pooled subjects included healthy normal subjects, and subjects diagnosed with AD in US (one study), UK (one study), Sweden (one study), Spain (one study). All the studies showed significant statistically difference in mini-mental-state examination (MMSE) between PSEN1+ and PSEN1-carriers. Details of the included studies are presented in Table 1 .
White matter mean diffusivity (MD) value
Combining the four studies using continuous mean diffusivity (MD) value and providing weighted mean differences (n=210 PSEN1+ population and n = 150 PSEN1-population), As shown in the forest plots ( Figure 2 ), yielded a statistically significant association between the PSEN1 mutation and 
PSEN1 and PET markers of AD
Description of included studies
The search strategy identified thirteen papers met the inclusion criteria for the PET-amyloid tracer study and for the FDG-PET study [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] . We did not found additional articles in the reference list of the selected studies. For the PET-amyloid tracer study, data from nine studies [37, [39] [40] [41] [42] 44, 45, 47] could not be used for analysis in this meta-analysis. The clinical, demographic and technical data of participants from all recruited studies in Table 2 [38, 46, 48, 49] . A total of 52 PSEN1+ subjects and 62
PSEN1-subjects were included. For the FDG-PET study, four studies met the selection criteria, including a total of 45 PSEN1+ subjects and 38 PSEN1-subjects. The detailed demographic and clinical data of participants from the five included studies are shown in the Table 2 .
PSEN1 and PET-amyloid tracers
The PSEN1 was significantly associated with increased amyloid deposition (test for overall effect: Z=2.1, p=0.035) , in a sample size-weighted meta-analysis,. Combined analysis of the association between the cortical SUVR and PSEN1 is shown in the forest plots ( Figure 3 ). The pooled SMD from a random- 
PSEN1 and FDG-PET for cerebral hypometabolism
The three included studies reported CMRgl reductions at cortex. A group comparison of 45 PSEN1+ subjects and 38 PSEN1-subjects was carried out. In PSEN1-subjects, CMRgl reductions at cortex were not found. Combined analysis of the relationship between the cortex white matter SUVR and PSEN1 is shown in the forest plots (Figure 4 ). The pooled SMD from a random-effects model was - 
Sensitivity analysis and publication bias
Publication bias have not been found for the association between PSEN1 mutation and MD value change was identified by Begg's funnel plot (P = 0.272). Additionally, publication bias have not been found for the association between PSEN1 mutation and cortical PiB-PET change was identified by
Begg's funnel plot (P = 0.079). We did not use funnel plot or additional methods to do sensitivity analysis due to the limited number of studies included, since only three studies met the inclusion criteria and were included into the FDG-PET and PiB-PET meta-analysis. However, all the included studies met the criteria were studies with a relatively large cohort.
Discussion
The main purpose of our study was to explore published literature and to attempt to elucidate PSEN1-related neural markers and AD. In this meta-analysis and systematic review, the PSEN1 gene is associated with abnormal white matter integrity and increased amyloid deposition.
Defects in brain function (such as white matter and gray matter) have provided important insights and predictions for brain changes in AD over the past two decades. Longitudinal studies have confirmed hippocampal defects in MCs before AD symptoms appear [50] . At each stage, the hippocampal volume of MC is smaller than the age-and sex-matched controls [5] . In addition to brain gray matter atrophy, DTI measurements (FA and MD value) indicating white matter damage
are commonly found in AD disease. During neurodegeneration, cell death leads to an increase in the diffusion of water molecules, which can be measured by elevated MD. Similarly, a reduced FA value indicates a process leading to a WM homogeneity disorder, indicating that WM integrity in the brain was disrupted [51] .
There is still confusion about the pathophysiology of white matter abnormalities in AD. Furthermore, it is unclear whether WM pathology is associated with gray matter (GM) pathology or independent of gray matter (GM) pathology. Studies have shown that Wallerian degeneration leads to abnormal white matter integrity [52] . At the same time, studies have shown that white matter abnormalities and gray matter pathology models exist simultaneously [53] . On the other hand, the retrograde hypothesis suggests that reducing WM integrity is caused by the separate decomposition of the myelin itself [8, 54] . As this theory suggests, early myelin bundles and small diameters will be affected first. Finally, local microvascular changes may also lead to WM pathology, as vascular damage also plays an important role in AD. Here, our results suggested that damage to white matter and gray matter may occur simultaneously and affect each other.
FA value change is also another important marker for abnormal WM integrity. In this study, due to our small sample size, we did not analyze the differences in FA value change. In previous study, Ringman et al reported decreased FA of the fornix in early symptomatic PSEN1-subjects were founded [18] . In the global brain scale, widespread decreased FA in symptomatic PSEN1-subjects was reported by Ryan et al [19] . Here, increased MD value in PSEN1-subjects was founded.
Some studies reports that gray matter defects, including brain atrophy, amyloid deposition and metabolic disruption in AD affect the left/posterior regions earlier than the right/anterior regions [55, 56] . In particular, in these regions, the MD value significantly increased and became more widespread and bilateral. Furthermore, the mean values of MD from these regions showed a negative correlation with CSF levels of Aβ42, associated with previous findings in sporadic AD [57] . The increased MD may be account for myelin loss, although the exact causes of these changes are difficult to clarify. In histological studies, a widespread decrease in myelin in WM of
normal appearance, and more severe myelin loss in AD were observed [58, 59] . Additionally, increased quantities of Aβ40 and Aβ42 accompanied by significant decreases in the amounts of myelin protein was found in biochemical analyses of WM from patients with AD [60] . Therefore, early AD brain pathology maybe detect by DTI measurements. Furthermore, MD appears to be more sensitive, compared with measures of FA and GM volume, during early pathological AD changes. [58] . Therefore, the pathological changes of gray matter and white matter were simultaneously detected. Our meta-analysis revealed that, in the case of PSEN1 mutation, the combination of the more sensitive MD value with the amyloid deposition of gray matter metabolism is expected to detect pathological changes of AD at an earlier time.
In AD disease, studies have shown that several different brain regions have been affected, which may lead to different severity of the disease and differences in symptoms. Here, we studied the situation of the main affected brain regions of different studies. All the brain areas changed included left inferior longitudinal fasciculus and cingulum and bilateral superior longitudinal fasciculus [35] ; Corpus callosum,Caudate, Accumbens, Amygdala, Hippocampus, Putamen [34] ;
Parr et al reported the brain area included corpus callosum and in the hippocampal part of cingulum bundle in the frontal and temporal lobes area [33] . Lee et al reported the areas included temporal and parietal lobes, the left frontal lobe and putamen [61] . All researches reported the MD
and FA values changed in the similar area, the all belong to the subcortical structures.
This study has several limitations. First, longitudinal studies are needed, for changes in GM, MD
were assessed at only one time-point. Second, although each acquisition parameter does not affect the quality of data, meta-analysis with different parameters is thus limited as it examines each parameter separately. For example, Firbank et al. [62] compared b values of 1000 and 4000 second/mm 2 and found that, 4000 second/mm 2 is more sensitive , additionally slice thickness is another important factor to get an improved signal-to-noise ratio. The third limitation is publication bias. For some relevant studies may not have been included in the database we searched and were missed in this study inevitably. In our meta-analyses, the number of subgroups divided by subjects was not sufficient to conduct a meta-analysis. At last, we were limited by the fact that most studies provided effect estimates for PSEN1 mutation, with varying different mutation types, over 180 different mutations in PSEN1 are known to cause AD and all mutation carriers develop early-onset AD (http://www.molgen.ua.ac.be/AD mutations).
In summary, this study indicates PSEN1 mutation associated with white matter changes and amyloid deposition occur in AD. Increased MD is observed and shows significant increased with amyloid deposition. However, CMRgl reductions at cortex were not found. We believe that these results will be useful to clarify the progression of AD pathology and valuable in the diagnosis of AD.
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